Clinical Trial: A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167914) titled 'A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants' on Sept. 03.

Brief Summary: This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Health Participants

Intervention: DRUG: SFG-02

Transdermal Formulation (SFG-02)

DRUG: Placebo

Transdermal Formulation (Placebo)

Recruitment Status: RECRUITING

Sponsor: Juro Sciences Inc.

Disclaimer: Curated...